Articles related to VITAMINS/SUPPLEMENTS

AREDS2 remains the evidence-based standard for AMD supplementation, but expanding understanding of complement dysregulation, mitochondrial dysfunction, and macular carotenoid biology has prompted discussion about whether a next-generation formulation could address pathways the current one does not target.

Glucosamine use was associated with a 25% increase in mortality risk in patients with Alzheimer’s disease-related dementia in a retrospective analysis of more than 50,000 patients, with no corresponding signal observed in those with mild cognitive impairment.

Bausch + Lomb launched PreserVision AREDS3, a reformulation of its established AREDS2 supplement adding a proprietary B-vitamin complex, citing a narrative review of more than 20 human studies linking B-vitamin supplementation to reduced AMD risk.

A retrospective ADNI cohort analysis found that omega-3 supplement users showed faster cognitive decline over 5 years than matched non-users, with FDG-PET evidence of reduced brain glucose metabolism.

Three recent studies examined associations between vitamin D status and outcomes across type 2 diabetes risk, Alzheimer’s biomarkers, and inflammatory bowel disease in exploratory cohorts.

A systematic review of five studies found no consistent short-term safety signals in renal, hepatic, or cardiometabolic outcomes among adolescents using creatine monohydrate.